Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment.

The Lombardy region of Italy was the second epicenter of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after China, with Bergamo province being the most affected area. The Hospital Papa Giovanni XXIII, the tertiary referral center for inflammatory bowel disease (IBD) in the whole province, was reconverted into a coronavirus disease 2019 (COVID-19) point of care, with up to 500 beds dedicated to patients with COVID-19 and more than 1,500 admissions for severe COVID-19 during the early phase of the local epidemic. To prevent SARS-CoV-2 spreading, from March 7, 2020, the Italian government ordered a total lockdown (LD) to confine the viral diffusion. From May 4, 2020, when the basic reproduction number (R0) dropped below 1 in the whole country, the LD was converted into phase 2 (P2), which envisaged a gradual reopening of work activities, provided the maintenance of 1-meter social distancing and the use of face masks.

Previous reports suggested that patients with IBD have an uneventful course during the SARS-CoV-2 pandemic, including those on biologic treatment. , Nonetheless, the rate of exposure to SARS-CoV-2 of these patients is currently unknown.

This study was designed to assess the seroprevalence of COVID-19 in patients with IBD undergoing biologic treatment during the main phase of the local epidemic. Furthermore, we investigated the risk factors for SARS-CoV-2 infection in this cohort of patients.

Patients and Methods

This study includes all patients with IBD (children and adults) undergoing biologic therapy (infliximab, adalimumab, golimumab, ustekinumab, and vedolizumab) followed at our center during the Italian COVID-19 outbreak.

The time period of enrollment was divided into 2 phases: LD (March 4–May 3) and P2 (May 4–July 10).

During LD, all patients were advised to continue their regular treatment and were screened for SARS-CoV-2 infection in the case of suspicious clinical symptoms or contact with ascertained infected patients.

From the beginning of P2, all patients were offered a rapid serologic test (VivaDiag COVID-19 immunoglobulin (Ig) G/IgM rapid lateral flow qualitative immunoassay, VivaChek Biotech, Hangzhou, China), performed by adding 10 μL of plasma and 2 drops of dilution buffer into the sample port. After 15 minutes, the results were evaluated by the same laboratory operator, who was unaware of the patient’s clinical and biochemical information.

The protocol was approved by the local ethical committee (protocol 141-20).

Results

A total of 103 patients with IBD on biologic treatment followed at our institution at the time of the study initiation completed a questionnaire exploring the presence of symptoms suggestive of SARS-CoV-2 infection as well as recent contacts with ascertained COVID-19 patients. Among them, 13 (12.6%) were younger than 18 years. All SARS-CoV-2–related symptoms reported by the patients were mild, and none required hospitalization for COVID-19 (Supplementary Table 1). Among them, 90 patients (87%) performed the serologic test, and 19 had positive results for IgG, IgM, or both. This resulted in a SARS-CoV-2 seroprevalence of 21%.

Supplementary Table 1

Characteristics of the Enrolled Cohort

Characteristics	Value
Total number	103
Female sex, n (%)	50 (48)
Age, y, median (range)	40 (22–50)
Disease, n (%)
Crohn’s disease	63 (61)
Ulcerative colitis	40 (39)
Biologic treatment, n (%)
Infliximab	36 (35)
Adalimumab	44 (43)
Vedolizumab	12 (11)
Ustekinumab	8 (8)
Golimumab	3 (3)
Concomitant immunosuppressive treatment, n (%)
Prednisone	2 (2)
Azathioprine	21 (20)
Treatment regimen, n (%)
Induction	11 (11)
Regular	88 (85)
Delayed	4 (4)
COVID-19 reported symptoms, n (%)	13 (13)
Fever	10 (9)
Cough	6 (6)
Dysgeusia/anosmia	5 (5)
Contacts with COVID-19–ascertained patients, n (%)	4 (4)

The comparison with a control group of health care personnel showed no significant difference in terms of global and age-stratified seroprevalence (P > .05) (Supplementary Figure 1).

Supplementary Figure 1

Comparison of the seroprevalence of SARS-CoV-2 between patients with IBD and the health care personnel of the Hospital Papa Giovanni XXIII. Data of seroprevalence in adult patients with IBD were compared with those of 4,395 health care workers screened between May and July 2020.

Remarkably, in univariate analysis, female sex, older age, and presence of reported symptoms were associated with a significant increased rate of positive serology (Table 1 ). The multivariate analysis confirmed the protective role of male sex, and older age had a 5-fold increased risk of positive serology result compared to younger age (47 years [older] vs 28 years [younger]). No positive pediatric cases were recorded. Eleven (58%) patients with a positive serology result reported no symptoms during the study period. Two patients, who had persistent fever and were eventually found to be positive on serology testing, underwent chest computed tomography that returned negative results for pulmonary involvement.

Table 1

Characteristics of Patients With IBD Undergoing Biologic Therapy According to Serology Test Results

Characteristics	n	Serology test results		P value
		Negative (n = 71)	Positive (n = 19)
Sex, n (%)
Female	90	29 (40.8)	13 (68.4)	.032a
Male		42 (59.2)	6 (31.6)
Age, y, median (IQR)	90	34.0 (19.0–47.0)	50.0 (28.0–57.0)	.020a
<28a		28 (39.4)	4 (21.1)	.019a
28–47a		24 (33.8)	3 (15.8)
≥47a		19 (26.8)	12 (63.2)
IBD type, n (%)
Ulcerative colitis	90	30 (42.3)	5 (26.3)	.21
Crohn’s disease		41 (57.7)	14 (73.7)
Biologic therapy, n (%)
Anti-TNF, n (%)	90	59 (83.1)	15 (78.9)	0.67
Adalimumab		30 (42.3)	10 (52.6)	.42
Infliximab		28 (39.4)	5 (26.3)	.29
Golimumab		1 (1.4)	0 (0.0)	.99
Anti-integrin (vedolizumab) , n (%)	90	8 (11.3)	1 (5.3)	.68
Anti-IL12/23 (ustekinumab) , n (%)	90	4 (5.6)	3 (15.8)	.16
Monotherapy/combination therapy, n (%)	90	13 (18.3)	5 (26.3)	0.44
Contact, n (%)	86	2 (3.0)	2 (10.5)	0.21
Symptoms, n (%)	87	4 (5.9)	8 (42.1)	<.001a
Fever	12	2 (50.0)	7 (87.5)	0.24
Cough	12	3 (75.0)	3 (37.5)	0.55
Dysgeusia/anosmia	12	0 (0.0)	5 (62.5)	.081

NOTE. Data are expressed as column percentages. Percentages may not reach 100% because of rounding

IL, interleukin; IQR, interquartile range; TNF, tumor necrosis factor.

Tertiles of age distribution.

Discussion

After more than 2 months from the first COVID-19 case in our region, we found that nearly one quarter of adult patients with IBD treated with biologics has been exposed to SARS-CoV-2 infection and that this figure is comparable to that of health care personnel working in their tertiary referral center. This suggests that the previously described uneventful course of IBD patients was not due to sheltering from the infection.

More than half of patients with positive SARS-CoV-2 serology results were completely asymptomatic during LD, and the others reported only mild symptoms. All biologic treatments were safely administered, even at high doses for the induction of remission. In this cohort, immunosuppressive treatment did not affect SARS-CoV-2 infection outcome.

Preliminary data suggest that immunosuppression is not an additional risk factor for the development of severe forms of SARS-CoV-2 infection, because it was also shown for the previous coronaviruses pandemics, SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome).

The only study assessing COVID-19 prevalence in patients with IBD was conducted in California and reported a 3% prevalence of disease, which was comparable to that of the general population. This retrospective study included patients who underwent SARS-CoV-2 nasopharyngeal testing mainly because of COVID-19–related symptoms; therefore, it cannot provide information on the rate of exposure to the infection of patients with IBD. Preliminary data of SARS-CoV-2 serology screening carried out by the Italian government found a 24% prevalence in the general population of the Bergamo province (https://www.istat.it/it/files//2020/08/ReportPrimiRisultatiIndagineSiero.pdf), which is comparable to the prevalence we found in our patients with IBD and health care personnel.

The high prevalence of patients with IBD having an asymptomatic course after SARS-CoV-2 infection is a matter of concern when it comes to scheduling hospital admissions for infusions, follow-up visits, or endoscopy in regions hit by SARS-CoV-2 and suggests the need for preadmission screening tests to prevent intrahospital dispersal of the virus. Previous findings suggesting nonadherence to biologic treatment are not confirmed in our cohort, where only 1 patient delayed the infusion because of fear of attending the hospital during the epidemic.

COVID-19 is mediated by an important cytokine storm. In COVID-19 patients, plasma concentrations of several cytokines, including tumor necrosis factor α, were remarkably increased compared to healthy control individuals, especially in those with more severe disease. According to that evidence and our findings, drugs aiming at blocking tumor necrosis factor α and interferon γ signaling pathways, if not beneficial, appear to be not harmful during SARS-CoV-2 infection.